Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15820MR)

This product GTTS-WQ15820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4702MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ3386MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ1216MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ10571MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9847MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ3161MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ7478MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW